France Dermatology Drugs Market Report 2022 to 2030

France Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the France dermatology drugs market will reach a value of $988 Mn from $468 Mn in 2022, growing at a CAGR of 9.8% during 2022-2030. The market is primarily dominated by local players such as Sanofi, Pierre Fabre Group, and Galderma Code. The market is driven by innovations like biological drugs, better health insurance, and an abundance of healthcare professionals. The dermatology drug market in France is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10FRPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Dr. Vishwa Modhia

Buy Now

France Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the France dermatology drugs market will reach a value of $988 Mn from $468 Mn in 2022, growing at a CAGR of 9.8% during 2022-2030.

In 2019, the out-of-pocket cost per person in France was $509, or 9.2% of the cost of healthcare. From 30% in 2014 to 24% in 2019, France's domestic private health spending has dramatically decreased. The French government has a universal health care program that is largely funded by national health insurance. Health spending in France accounted for 11.1 % of GDP in 2019, the highest share in the European Union.

In 2023, the OTC pharmaceuticals market of France is anticipated to generate $2,176 Mn in revenue. By 2023, the dermatology OTC drug market is projected to generate $274 Mn in revenue, representing 12% of France's overall OTC pharmaceutical market, up from $265.5 Mn in 2022.

france dermatology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

Biologics are a class of drugs that are derived from living organisms, such as proteins and nucleic acids. They are used to treat a wide range of conditions, including dermatological conditions such as psoriasis, eczema, and rheumatoid arthritis. In France, biologics are becoming an increasingly common treatment option for dermatological conditions. For example, biologics such as adalimumab, ustekinumab, and secukinumab are approved in France for the treatment of moderate-to-severe psoriasis.

Market Restraints

In France, there are more doctors and many more nurses, yet its healthcare system is still in crisis. But according to the World Health Organization, almost half of the French doctors are above the age of 55 and approaching retirement.

The revenue change in the dermatology segment has decreased from 5.5% in 2021 to 2.2% in 2022. This can discourage new players from entering the French dermatology drug market.

Competitive Landscape

Key Players

Sanofi (FRA)
Pierre Fabre Group (FRA)
Galderma Code (FRA)
A-Derma (FRA)
Bio derma (FRA)
Novartis
GlaxoSmithKline
Pfizer

Healthcare Policies and Regulatory Landscape

The health sector is regulated by the French Public Health Code, the French Social Security Code, the French Intellectual Property Code, the French Consumer Code, and EU regulations and directives.

Reimbursement Scenario

A cardinal metric system that reflects the added value of the product is used in France to determine the maximum reimbursement level and price for new medications. Each pharmaceutical product is given two ratings: one that reflects the product's actual medical benefit (SMR - Service Médical Rendu), which establishes the level of reimbursement, and another that assesses whether the medical benefit has improved (ASMR - Amélioration du service médical rendu), which determines whether a price premium can be achieved or whether a discount will be necessary.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.